Aducanumab
A monoclonal antibody against amyloid developed by Biogen, which underwent two parallel Phase 3 trials (EMERGE and ENGAGE) with mixed results but ultimately showed promise in high-dose groups. Its FDA approval decision is highly anticipated.
Videos Mentioning Aducanumab
164 - Diagnosing, preventing, & treating Alzheimer’s disease, & life lessons from dementia patients
Peter Attia MD
A monoclonal antibody against amyloid developed by Biogen, which underwent two parallel Phase 3 trials (EMERGE and ENGAGE) with mixed results but ultimately showed promise in high-dose groups. Its FDA approval decision is highly anticipated.
E35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, Bitcoin & more
All-In Podcast
Biogen's monoclonal antibody drug for Alzheimer's disease, approved by the FDA despite modest efficacy, costing $56,000 annually.
The Random Show, Couch Edition! — Supplements, Breathing and Balance Training, and Much More!
Tim Ferriss
An Alzheimer's drug mentioned as an example of a treatment focused on removing plaque, with clinical risks and uncertain cognitive benefits.